OPNT / Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

Opiant appears on track to be acquired for $20/share and offers various Contingent Value Rights (CVRs) linked to a potential drug launch. The drug hel more_horizontal

I love to get a CVR during a takeover process. This happens a lot when pharma or biotech companies with important unapproved assets get bought. more_horizontal

Opiant Pharmaceuticals (NASDAQ: OPNT ) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is off more_horizontal

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q1 2022 Results Conference Call May 10, 2022 4:30 PM ET Company Participants Ben Atkins - Vice President, more_horizontal

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced topline results from a pharmacodynamic (PD) study for OPNT003, nasal nalmefene for opioid overd more_horizontal

The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmace more_horizontal

The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmace more_horizontal

The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmace more_horizontal